Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events

ObjectivesIsoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France associated with poorer treatment outcomes compared drug-susceptible (DS-TB). The objective this study was to determine characteristics HR-TB patients compare safety for DS-TB.MethodsWe performed a case-control multicenter identify risk factors between DS-TB patients.ResultsCharacteristics 99 diagnosed treated university hospitals Paris, Lille, Caen Strasbourg were patients. Female sex (OR = 2.2; 1.0–4.7), birth West-Pacific World Health Organization region 4.6; 1.1–18.7) resistance streptomycin 77.5; 10.1–594.4) found be independently HR-TB. Rates success did not differ significantly DS-TB.ConclusionsFactors are significant enough efficiently screen at systematic implementation rapid molecular testing on clinical samples remains only effective way make early diagnosis adapt treatment.